FDA Approves ZYN’s Lower Risk Claim—Not Full Safety

FDA authorizes – The US FDA authorized 20 ZYN nicotine pouch products to carry a modified-risk claim, saying switching completely from cigarettes to ZYN lowers the risk of several smoking-related diseases. The approval doesn’t mean nicotine pouches are safe, and it doesn’t app

On June 30, the US Food and Drug Administration authorized 20 ZYN nicotine pouch products to carry a specific “modified risk” claim. In the US. ZYN can now say that “using ZYN instead of cigarettes puts you at a lower risk of mouth cancer. heart disease. lung cancer. stroke. emphysema and chronic bronchitis.”.

It sounds like a turning point. But the fine print matters just as much as the headline. The FDA authorization does not mean nicotine pouches are safe. and it is not an approval of nicotine pouches as a smoking-cessation product. Instead. the agency’s decision allows Swedish Match—which manufactures ZYN—to market certain products as a less harmful alternative for adults who completely switch away from cigarettes.

That distinction lands in a moment when nicotine pouches have already changed the conversation faster than regulators can keep up. Nicotine pouches have become one of the fastest-growing nicotine categories globally. driven by their discreet use. the absence of smoke or vapor. and a growing perception that they are a “cleaner” way to consume nicotine.

The numbers show how quickly the category is moving. A recent World Health Organization report put global retail sales of nicotine pouches at 23.4 billion units in 2024—an increase of more than 50 percent from the previous year. The WHO also warned that nicotine pouches are spreading so rapidly that regulation is struggling to keep pace in many countries. and that brands are increasingly leaning on social media. influencers. and youth-oriented marketing to promote them.

For many younger nicotine users, the FDA’s move may feel like official recognition of an idea they already embraced. The agency is formally endorsing the “switch from cigarettes” framing—something many users have already treated as the new normal. But it’s not a blessing for the category so much as a cautious catch-up, built on strict conditions.

Public health officials have been clear about why. The WHO has warned that nicotine pouches are becoming increasingly popular among adolescents and young adults because of their “strong youth appeal and high addiction potential.” That warning carries a practical concern: products initially marketed to smokers could end up attracting people who otherwise might not have turned to nicotine in the first place.

Based on toxicology data. consumer research. and public health modeling. the FDA issued a Modified Risk Tobacco Product (MRTP) order to 10 ZYN flavors at each of two strengths: 3 milligrams and 6 milligrams. Those designations allow Swedish Match to market those specific products as a lower-risk alternative for adults who switch completely away from cigarettes.

Still, the approval comes with two caveats that define who benefits—and who doesn’t.

First, the ruling applies to 20 specific products, not all nicotine pouches. Second, the FDA’s findings apply only to smokers who fully switch to these pouches. People who use cigarettes or vapes alongside pouches won’t get the same risk reduction. and the FDA has advised non-tobacco users against using nicotine pouches.

In explaining the intent behind the MRTP process. acting FDA Center for Tobacco Products director Bret Koplow said: “FDA’s review of modified risk products is intended to ensure that adult users have clear. science-based information about the relative harms of tobacco products. so they can make informed choices.” He added that the decision “informs adults who smoke about the lower risks associated with these products.”.

Swedish Match also has obligations that go beyond marketing language. The company must keep track of real-world usage and report back to the FDA. The MRTP order is valid for five years, unless it is renewed or withdrawn.

The FDA’s message. boiled down. is straightforward: adults who smoke and completely switch to certain nicotine pouches are likely reducing their health risks compared with continuing to smoke cigarettes. But the agency also stresses that there is no safe tobacco product. and that fully quitting all tobacco and nicotine products remains the best option for better health.

That leaves the question that sits outside the FDA’s math. Who ends up using nicotine pouches—and whether their rapid growth creates a new generation of nicotine users—is a separate story, and one the WHO has already warned regulators may struggle to manage as the market expands.

The broader landscape is already splintered. Nicotine-replacement therapies such as patches. gum. and inhalers remain FDA-approved tools intended to help people quit smoking. but they now face competition from a fast-growing ecosystem of alternatives. Oral nicotine pouches have quickly become one of the biggest growth categories, with ZYN and other brands like On!. and VELO among the front-runners globally.

Vapes and disposable e-cigarettes still take the biggest share of the global smoking-alternative category. projected to hit $14.8 billion by 2030 in the US—despite ongoing headlines about youth use. Heated tobacco devices like IQOS offer another option by heating tobacco instead of burning it. which lowers exposure to many harmful chemicals found in cigarette smoke.

In that crowded world. the FDA’s June 30 authorization draws a line between “less harmful” and “safe. ” and between switching completely and using multiple products at once. For adults who already smoke, the agency has now given ZYN an official pathway to make that reduced-risk claim. For everyone else—especially those the WHO worries about most—the approval doesn’t erase the core concern: nicotine itself can be a gateway. and regulation is still trying to catch up to demand.

FDA ZYN nicotine pouches modified risk tobacco product Swedish Match tobacco regulation World Health Organization youth marketing harm reduction cybersecurity not applicable digital trends not applicable